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ABSTRACT
Background and aims Increasing the reach of smoking cessation services and/or including new but effective medica-
tions to the current provision may provide signiﬁcant health and economic beneﬁts; the scale of such beneﬁts is currently
unknown. The aim of this study was to estimate the cost-effectiveness from a health-care perspective of viable national
level changes in smoking cessation provision in the Netherlands and England.Methods AMarkov-based state transition
model [European study on Quantifying Utility of Investment in Protection from Tobaccomodel (EQUIPTMOD)] was used to
estimate costs and beneﬁts [expressed in quality-adjusted life years (QALY)] of changing the current provision of smoking
cessation programmes in the Netherlands and England. The changes included: (a) increasing the reach of top-level services
to increase potential quitters (e.g. brief physician advice); (b) increasing the reach of behavioural support (group-based
therapy and SMS text-messaging support) to increase the success rates; (c) including a new but effective medication
(cytisine); and (d) all changes implemented together (combined change). The costs and QALYs generated by those changes
over 2, 5, 10 years and a life-timewere compared with that of the current practice in each country. Results were expressed
as incremental net beneﬁt (INB) and incremental cost-effectiveness ratio (ICER). A sequential analysis from a life-time per-
spective was conducted to identify the optimal change. Results The combined change was dominant (cost-saving) over
all alternative changes and over the current practice, in both countries. The combined change would generate an incre-
mental net beneﬁt of €11.47 (2 years) to €56.16 (life-time) per smoker in the Netherlands and €9.96 (2 years) to €60.72
(life-time) per smoker in England. The current practice was dominated by all alternative changes. Conclusion Current
provision of smoking cessation services in the Netherlands and England can beneﬁt economically from the inclusion of
cytisine and increasing the reach of brief physician advice, text-messaging support and group-based therapy.
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INTRODUCTION
A decade after the Framework Convention on Tobacco
Control (FCTC) the smoking prevalence among adults in
Europe is still high, at 28% [1,2]. The FCTC introduced
the MPOWER package, aiming to achieve progress in
various aspects from effective monitoring of tobacco
control efforts to offering help to people who want to stop
smoking [2]. However, the actual action taken after ratify-
ing MPOWER has been inconsistent throughout Europe,
which has led to some countries being more successful in
decreasing their smoking prevalence [3]. Nevertheless,
the ‘O’ of the MPOWER—offer help to people who want
to stop smoking—has been a key policy driving the fall in
smoking prevalence [3].
A previous study describing a survey of tobacco
control activity in 34 European countries suggested that
the United Kingdom is leading in Europe with successful
anti-tobacco policies, including taxation on tobacco
products, a smoking ban in public places, advertisement
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bans and treatment offers to stop smoking [3]. This has
contributed to a decrease in smoking prevalence from
25% in 2003 to 18% among people aged over 16 in
2013 [4,5]. The Netherlands was ranked 13th in the same
study [3]. The smoking prevalence in the Netherlands was
30.8% in 2003 and decreased to 25.6% among people
aged over 16 in 2013 [6,7]. However, current services
have experienced variation in effectiveness, and smoking
prevalence thus remains high [1,4,6].
Good-quality evidence around the effectiveness and
cost-effectiveness of interventions used in the current
provision of smoking cessation services is available [8].
However, it is less clear whether reorganizing the current
provision, with an aim to achieving efﬁciency savings or
improving reach, would deliver a better return on invest-
ment. As smoking cessation services are currently under
threat from disinvestment due to funding cuts, the answers
to the above policy questions are timely. Increasing the
reach of smoking cessation services and/or including new
but effective medications (e.g. cytisine) to the current
provision may provide signiﬁcant health and economic
beneﬁts. However, the scale of such beneﬁts is currently
unknown. Therefore, the aim of this study was to estimate
the cost-effectiveness from a health-care perspective
of viable national level changes in smoking cessation
provision in the Netherlands and England. A European
return-on-investment (ROI) model [European study on
Quantifying Utility of Investment in Protection from
Tobacco model (EQUIPTMOD)] was utilized for this study,
with a view to guiding future investment decisions. This
analysis was therefore restricted to two countries only
(England and the Netherlands), as they have similar
current provision of smoking cessation services compared
to the other three EQUIPTMOD countries.
METHODS
Study design
The EQUIPTMOD [9], a Markov-based state transition
economic model, was used to estimate the level of: (a) in-
vestment required to implement national level changes to
smoking cessation services; and (b) potential beneﬁts such
changes would generate in the Netherlands and England.
The EQUIPTMOD is based on an earlier version of a
tobacco ROI tool developed for National Institute for Health
and Care Excellence (NICE) [10]. A cohort of current
smokers are followed-up for various time horizons
(including life-time) to capture costs and quality-adjusted
life years (QALY) gains, as receiving treatment (services)
would alter their risk of developing smoking-attributable
diseases (lung cancer, coronary heart disease, chronic
obstructive pulmonary diseases and stroke). In each cycle
(year), the model takes in to account the balance of
quittingand relapsing through a background quit rate. Full
details about the model workings and assumptions are
described elsewhere [9]. Various time horizons (2, 5,
10 years and life-time), discount rates of 3.5% for costs
and effects (England) and 4% for costs and 1.5% for
effects (Netherlands) [11] and health-care perspectives
were taken.
Population, intervention, comparator and outcomes
This study included national populations of England and
the Netherlands. Table 1 summarizes the key population
attributes, as captured from a review of various sources
by the EQUIPT Study Group [12,13].
A number of smoking cessation interventions are
implemented currently in the Netherlands and England.
Table 2 summarizes the interventions included in the
EQUIPTMOD. The selection of interventions was the result
of best-evidence review [14]. The interventions were
grouped into three broad categories: (a) top-level inter-
ventions that encourage smokers to make quit attempts
(e.g. brief physical advice); (b) pharmacological interven-
tions that encourage those smokers already making
quit attempts to succeed through use of a medication;
and (c) behavioural interventions that encourage those
smokers already making quit attempts to succeed through
counselling, self-help materials or mobile phone support.
Although England and the Netherlands have similar
smoking cessation services among the countries included
Table 1 Population size, smoking prevalence and potential quitters and current use of smoking cessation services [4,6].
the Netherlands England
Adult population (> 16) 13870 426 43813787
Smoking prevalence (%) 25.60% 17.99%
Number of smokers making a quit attempt in the next 12 months (% of smokers) 949 945 (26.75%) 2 236 287 (28.37%)
Use pharmaceutical support (% of those smokers making a quit attempt in the next
12 months)
39.95% 34.70%
Use behavioural therapy (% of those smokers making a quit attempt in the next 12 months) 8.92% 8.61%
Combination pharmaceutical and behavioural therapy (% of those smokers making a quit
attempt in the next 12 months)
8.32% 5.88%
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in the EQUIPTMOD, it is important to note a few key differ-
ences in the way these interventions are delivered in
England and the Netherlands. In England, the responsi-
bility for public health services, including smoking cessa-
tion, is in the hands of local authorities [15]. The Local
Stop Smoking Services (LSSS) is free to use for all UK
residents. The pharmacological and behavioural support
options are available for the smokers to choose. In the
Netherlands, the smoking cessation programme under
the basic insurance package includes visit(s) to a general
practitioner (GP) [16]. The GP and the patient decide in
consensus which help is needed. Pharmaceutical and/or
behavioural support must be prescribed by a physician
to be covered by insurance.
Behavioural support is offered both in the Netherlands
and England. This can be one-to-one behavioural support,
group-based behavioural support, telephone support
(proactive), short messaging service (SMS) text messaging
or printed self-help materials. Specialist behavioural
support on a one-to-one basis consists of practical advice
and emotional support and encouragement based on the
Maudsley model by a health professional trained to the
National Centre for Smoking Cessation and Training
(NCSCT) standard or equivalent. Group-based behavioural
support is a group discussion based on the Maudsley model
in a group of six to 30 smokers [17]. This is also delivered
by a health professional, as is the proactive telephone
support. This telephone support entails practical advice
and emotional support and encouragement according to
principles set out in the National Health Service (NHS)
and Monitoring Guidance or similar. SMS text messaging
support is provided by an automated system that sends
multiple texts per day containing practical advice and
encouragement. Printed self-help materials also give prac-
tical advice and encouragement; these are either one-off
book/booklets or multiple booklets.
Intervention attributes (costs, effects and reach) are
described in Table 2. Reach refers to the proportion of
smokers who currently make a quit attempt in a given
year who are exposed to the intervention. Effect size refers
to the ratio of the proportion of smokers exposed to the
intervention who are estimated to achieve 12 months of
smoking abstinence compared with not receiving the
intervention, other things being equal. Effect sizes are
point estimates and subject to both a margin of error
because of sampling variation in the studies and also true
variation as a function of variation in the delivery of the
intervention. Relevant caveats of these estimates are
discussed fully elsewhere [18]. These data were derived
from the literature or estimated, and costs were adjusted
for inﬂation if they were from previous years. As data on
reach of smoking cessation services in the Netherlands
were not available, English estimates were used for Dutch
intervention usage [10,19].
For the purposes of this analysis, we deﬁned ﬁve inter-
vention packages that reﬂected alternative changes to the
current provision of services (i.e. current practice). The
current practice was the base comparator. The current
Table 2 Interventions considered in the cost-effectiveness modelling [12–14].
Costs per person
Effect size ReachaNetherlands (€, 2015) England (£, 2015)
Top-level interventions
Brief physician (GP) advice 30.00 19.48 1.40 21%
Cut down to quit Not applicable 212.38 2.10 12% in England
0% in Netherlands
Pharmaceutical interventions
Rx mono NRT 225.05 106.44 1.60 5.00%
Rx combo NRT 465.24 203.16 2.14 2.00%
Varenicline (SD) 325.71 191.88 2.30 5.00%
Varenicline (extended duration) 612.42 355.68 2.76 1.00%
Bupropion 175.78 79.98 1.60 1.00%
Cytisineb 24.29 17.63 3.98 0.00%
Behavioural interventions
Specialist behavioural support: one-to-one 465.00 120.64 1.40 2.00%
Specialist behavioural support: group-based 41.90 36.77 2.00 1.00%
Telephone support: proactive 119.00 [31] 151.67 1.40 0.50%
SMS text messaging 23.68a 16.92 1.71 0.50%
Printed self-help materials 1.21 13.03 1.19 1.00%
aFigures from England where no corresponding ﬁgure for the Netherlands was available; bNot currently licensed for use in both countries. NRT = nicotine
replacement therapy; SD = standard deviation; GP = general practitioner; SMS = short messaging service.
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practice included all interventions listed in Table 2 at their
current levels of reach.
Alternative changes were identiﬁed as a prospective
change in the current practice either by increasing or de-
creasing the reach of the interventions or including new
but effective interventions. The size and feasibility of the
change were testedwith a Dutch policymaker andwas also
informed by previous stakeholder analyses [20]. As shown
in Table 3, changes A, B and C reﬂected increasing the
reach of brief physician advice, the SMS text messaging
support and group-based therapy. In change D, a new
but effective cessation pharmacotherapy—cytisine—was
included. A recent review has found that although cytisine
is not used widely in western countries, it has been shown
to be effective [18]. Cytisine is not currently licensed for use
in both England and the Netherlands. In change E, we
assumed that changes A–D would be implemented
together (called, a combined change).
The ﬁnal outcomes included QALYs generated by each
change and the current practice, as recommended by the
National Institute for Health and Care Excellence (NICE)
and also recommended by the Dutch guideline for
economic evaluations [21]. In this paper, ‘costs’ refers to
the sum of two cost components: (i) costs required to
deliver an intervention package; and (ii) costs associated
with treating the smoking-attributable diseases.
Analyses
Two levels of analyses were conducted. First, we estimated
QALYs gained per 1000 smokers and incremental net
beneﬁt (INB) per smoker over four time horizons (2, 5,
10 years and the life-time of current smokers). To estimate
the INB, a QALY gain was converted to € using the
cost-effectiveness threshold of GB£ 20000 as recom-
mended by NICE in England [22] and €25000 in the
Table 3 Alternative changes to the current provision examined in the study.
Change Description Implications
A Increase reach: brief physician advice
Rationale: with brief physician advice there is a relative increase of 1.4 in the percentage of
smokers making a quit attempt in the next 12 months compared to the percentage making
a quit attempt in the next 12 months at baseline [32]. The costs of a brief physician advice
are €30.00 per smoker in the Netherlands and £19.48 in England [31].
Aim: increase the percentage of smokers receiving a brief physician advice from 21 to 22%
Number of smokers making
quit attempts may increase
B Increase reach: specialist group-based behavioural therapy
Rationale: group-based therapy has a relative effectiveness of 2.0, whereas one-to-one
therapy has a relative effectiveness of 1.4 [33]. Group-based therapy costs €41.90 in the
Netherlands and £36.77 in England [10,21,22], one-to-one therapy costs €465.00 in the
Netherlands and £121.64 in England [31,34]
Aim: decrease the number of people receiving one-to-one specialist behavioural therapy by
25%, and assume that these people use group-based specialist behavioural therapy instead
Success rate of the quit
attempts in specialist
behavioural therapy may rise,
while the costs may decrease
C Increase reach: SMS text-messaging support
Rationale: SMS text-messaging support is €23.68 per person in the Netherlands and
£16.92 in England [35], and has a relative effectiveness of 1.71 [36]
Aim: increase the number of people receiving SMS text-messaging support by 25%
Success rate following quit-
attempts by smokers on text
messaging support may
increase
D Include new but effective pharmacotherapy (cytisine)
Rationale: nicotine receptor partial agonists such as varenicline or cytisine aim to reduce
withdrawal symptoms and thus increase the chance of success in quit attempts. Cytisine, a
similar medication to varenicline, is not yet licensed for use in the Netherlands and UK but
has been found to be effective (RR = 3.98) in trials [37] and potentially cost-effective in
modelling studies [28]. Including cytisine, which is signiﬁcantly cheaper than varenicline,
to the current provision of smoking cessation services may therefore provide better value for
money (case for license and use)
Aim: assume 50% of smokers currently using varenicline (standard duration) will use
cytisine instead
Success rate of quit-attempts
by smokers on cytisine may
rise, while the costs may
decrease
E Combined change
Rationale: encouraging more smokers to make quit attempts, improving the reach of
services for those who have made quit attempts, and including new but effective cessation
medications, together may lead to more successful quitters than the current provision of
smoking cessation services
Aim: combine changes Awith B, C and D
Implementation costs may be
higher but could be offset by
the beneﬁts from increased
number of quitters
RR = relative risk; SMS = short messaging service.
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Netherlands [23]. This is a standard approach taken in
health economic evaluations, but is subject to debate
because a threshold value also reﬂects political will and
ﬁnancial constraints in a country. Nevertheless, INBs are
easy to interpret and thus may be useful in decision
making. A positive value of INB demonstrates that the ben-
eﬁts exceed the costs, and hence a positive ROI is expected.
Costs were expressed in £ for England, and were then con-
verted to € for comparison purposes (£0.72584= €1) [12].
The QALY gains and corresponding INB estimates
provided the ﬁrst level analyses showing the extent of net
beneﬁt that would be generated over time by respective
changes A–E, compared to current practice. Next, a sequen-
tial analysis was conducted to determine which alternative
change was optimal (i.e. provided the best value for money).
This was performed by identifying ‘dominance’ and
‘extended dominance’, the terms used by health economists
to refer to the process of eliminating less cost-effective
options from the choice set [24]. For this, current practice
(base comparator) and alternative changes A–E were ﬁrst
ranked by outcomes (QALYs per smoker) from low to high.
A ‘dominated’ alternative had either higher expected costs
and lower expected outcomes than another comparator;
or higher expected costs and the same expected outcomes
as another comparator; or the same expected costs and
lower expected outcomes as another comparator.
An alternative was subject to ‘extended dominance’
when it could not be considered cost-effective regardless
of a decision maker’s threshold value for an outcome. For
this, once all dominated alternatives were eliminated and
remaining alternatives were placed in ascending order of
outcomes, the incremental cost-effectiveness ratio (ICER)
was calculated for each alternative versus the preceding
alternative. If the ICER for, for instance, an alternative X
was lower than that for another alternative, for instance,
Y, and X had greater effectiveness than Y, Y was subject
to ‘extended dominance’ through both X and the base
comparator. This process led to the identiﬁcation of the
most cost-effective alternative among the choice set.
As the conﬁdence interval for the relative risk showing
effectiveness of cytisine is wide [2.01, 7.87], a deterministic
(univariate) sensitivity analysis was conducted to ascertain
whether the QALY gains and INB were sensitive to
cytisine’s effectiveness values. The results were depicted
in a tornado diagram. No probabilistic sensitivity analysis
was conducted, but the implication of this for the study’s
conclusions is considered in the Discussion section.
RESULTS
Table 4 presents the QALY gains per 1000 smokers and
corresponding incremental net beneﬁt values (per smoker)
Table 4 Short-, medium- and long-term beneﬁts of alternative changes A–E compared with the current provision.
Change Time horizon
Netherlands England
QALYs gained
per 1000
smokers
Incremental
net beneﬁt
(€ per smoker)
QALYs gained
per 1000
smokers
Incremental
net beneﬁt
(£ per smoker)
Incremental net beneﬁt
(€ per smoker)
(£0.72584 = €1)
A. Increase reach: GP brief
advice
2 years 0.0043 0.38 0.0050 0.15 0.21
5 years 0.0113 0.14 0.0129 0.05 0.07
10 years 0.0240 0.27 0.0259 0.37 0.51
Life-time 0.1049 2.53 0.0803 1.62 2.25
B. Increase reach: group-
based behavioural therapy
2 years 0.0110 2.51 0.0125 0.75 1.03
5 years 0.0290 3.13 0.0320 1.24 1.71
10 years 0.0620 4.19 0.0643 2.03 2.80
Life-time 0.2704 10.02 0.1997 5.15 7.10
C. Increase reach: SMS text-
messaging support
2 years 0.0032 0.09 0.0037 0.08 0.11
5 years 0.0086 0.27 0.0095 0.22 0.30
10 years 0.0183 0.58 0.0190 0.46 0.63
Life-time 0.0800 2.31 0.0591 1.38 1.90
D. Include new but effective
pharmacotherapy (cytisine)
2 years 0.0461 9.19 0.0824 6.51 8.97
5 years 0.1218 11.78 0.2102 9.75 13.43
10 years 0.2602 16.23 0.4229 14.95 20.60
Life-time 1.1351 40.70 1.3137 35.45 48.83
E. Combined change 2 years 0.0653 11.47 0.1049 7.23 9.96
5 years 0.1727 15.15 0.2677 11.35 15.64
10 years 0.3690 21.45 0.5384 17.98 24.77
Life-time 1.6098 56.16 1.6726 44.07 60.72
GP = general practice; SMS = short messaging service.
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for all time horizons included in the study. As expected, the
beneﬁts of the changes A–E compared with current
practice increased over time. For example, change A in
the Netherlands led to QALY gains of 0.0043 per 1000
smokers in 2 years but it increased to 0.1049 over the
life-time. The corresponding incremental net beneﬁt values
were –€0.38 per smoker in 2 years (a net loss) but €2.53
per smoker during the life-time (a net gain). A similar trend
was observed for England, although QALY gains per 1000
smokers were generally higher in England than in the
Netherlands. Change A delivered the least beneﬁt while
change E delivered the most beneﬁts on all time horizons.
Changes B–D led to a positive return on investment from
the second year onwards, while change A did so from the
5th year onwards only in England and during the life-time
in the Netherlands (Table 4).
Table 5 presents the modelling results (life-time costs
and QALYs per smoker) to aid the sequential analysis.
The current practice was dominated by all scenarios.
Changes A and C were dominated by changes D, B and E;
change B was dominated by D and E; and change D was
dominated by E. Change E was dominant overall.
Figure 1 presents a tornado diagram showing the
sensitivity of INB estimates to cytisine effect size values over
Table 5 Sequential analysis of changes A–E for the Netherlands and England.
Changea
QALYs per
smoker
(Netherlands)
Costs (€) per
smoker
(Netherlands)
QALYs per
smoker
(England)
Costs (£) per
smoker
(England)
Costs (€) per
smokerb
(England)
Both the
Netherlands and
England
Current practice 20.9537 18301.80 14.7909 11717.49 16143.35 Dominated by
all
C. Increase reach: SMS text-
messaging support
20.9538 18301.49 14.7910 11717.30 16143.08 Dominated by
D, B and E
A. Increase reach: GP brief
advice
20.9538 18301.89 14.7910 11717.48 16143.33 Dominated by
D, B and E
B. Increase reach: group-
based behavioural therapy
20.9540 18298.54 14.7911 11716.34 16141.77 Dominated by D
and E
D. Include new but effective
pharmacotherapy (cytisine)
20.9548 18289.47 14.7923 11708.32 16130.72 Dominated by E
E. Combined change 20.9553 18.285.88 14.7926 11706.87 16128.73 Dominant over
all
aChanges A–E are ranked by ascending QALYs per smoker values. Costs and effects are discounted. bConversion rate £0.72584 = €1. GP = general practice;
SMS = short messaging service.
Figure 1 Tornado diagram showing the sensitivity of incremental net beneﬁt to cytisine’s effect size values for various time horizons in England and
the Netherlands [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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all time horizons for England and the Netherlands. For this,
lower (=2.01) and upper values (=7.87) of relative risk
(RR) were used. With the lower value of RR, the INB
estimates varied by between 21% (2 years) and 96%
(life-time) for theNetherlands and between39% (2 years)
and 103% (life-time) for England, compared with the
base case value as reported in Table 4. With the upper
value of RR, the INB estimates varied by between +42%
(2 years) and +189% (life-time) for the Netherlands and
between +77% (2 years) and +203% (life-time) for
England. Both values nevertheless provided positive INB
values overall, except for one (the life-time INB with lower
RR value in England was negative).
DISCUSSION
Summary of the key ﬁndings
Our analysis suggested that certain changes to the current
provision of the smoking cessation services may provide a
better ROI compared to the current practice. This was
observed in both the Netherlands and England, although
the actual ROI was slightly different between the countries.
In particular, increasing the reach of brief GP advice, SMS
text messaging support and group-based behavioural
therapy as well as including cytisine (which is not
currently licensed for use in both countries) as a cessation
medication could be cost-effective policy changes.
Implementing all those changes together would be the
most cost-effective policy option.
To appreciate the results fully, it may be worth compar-
ing the differences in smoking-related data in the two
countries. The smoking prevalence in older age groups
(Supporting information, Appendix Supplementary infor-
mation) is higher in the Netherlands than in England,
which may have resulted in fewer QALY gains [4,25].
The costs of treating smoking-attributable diseases in
the Netherlands are much higher than in England
(Supporting information, Appendix Supplementary infor-
mation). Together, thesemay have resulted in the interven-
tion effects being more favourable in England than in
the Netherlands.
Implications of the ﬁndings
This study provides the English and the Dutch decision-
makers with ﬁnancial justiﬁcations for considering poten-
tial changes that could be made to improve the ROI from
existing smoking cessation services. If the current smoking
cessation services can be reorganized, as suggested in this
study, more smokers would make a successful quit attempt.
Health gains and cost savings would thus go hand in hand.
In particular, this study makes a business case for licensing
cytisine, a less costly alternative to varenicline, for use in
the current stop smoking services. Decision-makers now
have this important information, as they aim to implement
the FCTC more effectively [2].
Comparison with the wider literature
A systematic review of effectiveness studies on the NHS
smoking cessation services by Bauld et al. [26] showed that
the services were effective in successfully people to stop
smoking supporting in the short- and long terms. Another
systematic review by West and colleagues [18] suggested
that smoking cessation services are also effective and af-
fordable in middle- and high-income countries [8]. How-
ever, it was less clear whether these interventions when
implemented collectively (current practice) would be as
cost-effective as when the current provision is reorganized
to improve the reach and cut costs. Our study investigated
this important policy question by quantifying the net ben-
eﬁt from implementing certain changes to the current pro-
vision. The changes analysed in this study are viable policy
options (but subject to licensing regulations in the case of
cytisine). Therefore, our analysis is expected to encourage
similar future studies, e.g. evaluation of potential cost-
effective changes by including computer-tailored eHealth
programmes in the Netherlands [27]. This analysis also
supports the ﬁndings from a previous modelling exercise
that looked at the cost-effectiveness of cytisine versus
varenicline [28]. However, we extend this knowledge
by estimating the probable return on investment if
cytisine was included to the current provision of stop
smoking services.
Limitations of the study
This study has a few limitations. First, the analyses
presented in this study are based on the EQUIPTMOD,
and this has meant that the results presented here are
subject to the limitations of the model itself [9]. Secondly,
although the costs internal to the model (e.g. increased
cost of group-based behavioural therapy when its reach is
increased) are taken into account in generating ROI
metrics, we acknowledge that there may be other costs ex-
ternal to the model (e.g. cost of designing a policy change)
which were not considered in the analysis. Given the
unavailability of data, we could not be certain to what
extent adding such costs would change our conclusions;
our best guess is that it would not, given the observed size
of the incremental net beneﬁts before such costs were
considered. Thirdly, we were not able to assess the extent
of practicality of the recommended policy changes; rather,
the aim of this analysis is to generate this debate in the
policymaking circle. Fourthly, our analysis considered the
cost of a full implementation of interventions (e.g. a full
course of cytisine was assumed). In real-world practice,
however, most smokers relapse/fail to quit and hence
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stop using medication, and even those who quit success-
fully do not use a full course. Our study might therefore
have overestimated the implementation costs. However,
for the purpose of ROI modelling here, we assumed
that a full course of treatment was necessary in order for
the interventions to be as effective as in the original
trials [18].
Finally, we could not assess the uncertainty concerning
point estimates presented in this analysis due to the design
of the EQUIPTMOD (i.e. the user interface currently does
not support uncertainty estimates for sequential analysis).
Given that uncertainty in point estimates from the model
has been tested elsewhere, both deterministically and prob-
abilistically [29,30], the overall estimates presented here
may still be robust. With regard to cytisine, the univariate
sensitivity analysis presented here suggested that the ROI
estimates were sensitive to the uncertainty concerning
the effect size of the medication. However, even with the
lower value of RR, one could expect a positive incremental
net beneﬁt from the inclusion of cytisine to the current pro-
vision of stop smoking services.
CONCLUSION
Current provision of smoking cessation services in the
Netherlands and England can beneﬁt from some viable
national level changes such as the inclusion of cytisine as
a cessation treatment as well as increasing the reach of
brief physician advice, text messaging support and group-
based therapy.
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